Based on the current stage of clinical development and estimated trial completion dates registered on ClinicalTrials.gov, a realistic earliest possible timeline might be considered as follows: 20252026: Completion of key phase 3 TRIUMPH trial data 20262027: Potential regulatory submission to the MHRA (and FDA/EMA in parallel) 20272028: Possible MHRA marketing authorisation, subject to satisfactory review 2028 onwards: NICE technology appraisal and potential NHS commissioning decision These timelines are speculative and depend on multiple variables, including trial outcomes, the completeness of the regulatory submission, MHRA review timelines, and NICE deliberations
An additional study explored the vitamins, minerals, and nutrients that GLP-1 users typically fall short on, and how these are essential for neurochemical balance and cognitive function
The diabetes GLP-1 market (for type 2 diabetes treatment) similarly shows continued expansion, partly due to new patients being prescribed these powerful agents
Frequently Asked Questions Is bruising from my semaglutide injection a sign the medication isn't working
Martn G
Partner with us to access premium research-grade tools and professional support tailored to accelerate your scientific discoveries effectively
